Jun 25, 2024 · People with COVID-19 have a wide range of symptoms ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. Symptoms may start as mild, and some people will progress to more severe symptoms.

Find links to guidance and information on all topics related to COVID-19, including the COVID-19 vac

CDC’s home for COVID-19 data. Visualizations, graphs, and data in one easy-to-use website.

COVID-19 (coronavirus disease 2019) is a disease caused by the SARS-CoV-2 virus. It can be very contagious and can spread quickly. As of June 1, 2024, nearly 1.2 million people have died of COVID-19 in the U.S.

Las personas con COVID-19 tienen una amplia gama de síntomas que van de síntomas leves a enfermedades graves. Los síntomas pueden aparecer de 2 a 14 días después de la exposición al virus. Los síntomas pueden empezar siendo leves, y en algunas personas se intensificarán hasta llegar a ser graves.

Wearing a mask and putting distance between yourself and others can help lower the risk of COVID-19 transmission. Testing for COVID-19 can help you decide what to do next, like getting treatment to reduce your risk of severe illness and taking steps to lower your chances of spreading COVID-19 to others.

Dec 20, 2024 · A COVID-19 vaccine is the first step to prevent severe health outcomes. Antiviral treatments are not a replacement for COVID-19 vaccinations. COVID-19 vaccines available in the United States effectively protect people from getting …

Dec 20, 2024 · Conozca los tipos de tratamiento para el COVID-19, cómo tratar los síntomas y cómo recuperarse.

Jan 7, 2025 · Everyone ages 6 months and older should get a 2024–2025 COVID-19 vaccine. The COVID-19 vaccine helps protect you from severe illness, hospitalization, and death. It is especially important to get your 2024–2025 COVID-19 vaccine if you are ages 65 and older, are at high risk for severe COVID-19, or have never received a COVID-19 vaccine.

Today, CDC Director Mandy Cohen endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation for people 65 years and older and those who are moderately or severely immunocompromised to receive a second dose of 2024-2025 COVID-19 vaccine six months after their first dose.